Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss

Nora E. Straznicky1*, Mariee T. Grima1, Carolina I. Sari1, Elisabeth A. Lambert1,2,9, Sarah E. Phillips1, Nina Eikelis1, Daisuke Kobayashi1, Dagmara Hering2, Justin A. Mariani3,6, John B. Dixon1,8, Paul J. Nestel4, Sofie Karapanagiotidis5, Markus P. Schlaich2,6,7 and Gavin W. Lambert1,6

Abstract
Background: The hyperinsulinemia of obesity is a function of both increased pancreatic insulin secretion and decreased insulin clearance, and contributes to cardiovascular risk. Whilst weight loss is known to enhance insulin clearance, there is a paucity of data concerning the underlying mechanisms. This study was conducted to examine the inter-relationships between changes in sympathetic nervous system (SNS) activity, vascular function and insulin clearance during a weight loss program.

Methods: Seventeen non-smoking, un-medicated individuals aged 55 ± 1 years (mean ± SEM), body mass index (BMI) 33.9 ± 1.7 kg/m², underwent a 4-month hypocaloric diet (HCD), using a modified Dietary Approaches to Stop Hypertension diet, whilst seventeen age- and BMI-matched subjects acted as controls. Insulin sensitivity and insulin clearance were assessed via euglycemic hyperinsulinemic clamp (exogenous insulin clearance); hepatic insulin extraction was calculated as fasting C-peptide to insulin ratio (endogenous insulin clearance); SNS activity was quantified by microneurographic nerve recordings of muscle sympathetic nerve activity (MSNA) and whole-body norepinephrine kinetics; and vascular function by calf venous occlusion plethysmography and finger arterial tonometry.

Results: Weight loss averaged −8.3 ± 0.6 % of body weight in the HCD group and was accompanied by increased clamp-derived glucose utilization (by 20 ± 9 %, P = 0.04) and exogenous insulin clearance (by 12 ± 5 %, P = 0.02). Hepatic insulin extraction increased from 6.3 ± 0.8 to 7.1 ± 0.9 (P = 0.09). Arterial norepinephrine concentration decreased by −12 ± 5 %, whole-body norepinephrine spillover rate by −14 ± 8 %, and MSNA by −9 ± 5 bursts per 100 heartbeats in the HCD group (P all >0.05 versus control group). Step-wise regression analysis revealed a bidirectional relationship between enhanced exogenous insulin clearance post weight loss and reduction in calf vascular resistance (r = −0.63, P = 0.01) which explained 40 % of the variance. Increase in hepatic insulin extraction was predicted by enhanced finger reactive hyperaemic response (P = 0.006) and improvement in oral glucose tolerance (P = 0.002) which together explained 64 % of the variance.

Conclusions: Insulin clearance is independently and reciprocally associated with changes in vascular function during weight loss intervention.

Trial registration ClinicalTrials.gov: NCT01771042 and NCT00408850

Keywords: Insulin clearance, Weight loss, Vascular resistance, Obesity, Norepinephrine kinetics

*Correspondence: nora.straznicky@bakeridi.edu.au
1 Laboratory of Human Neurotransmitters, Baker IDI Heart and Diabetes Institute, P.O. Box 6492, St Kilda Road Central, Melbourne, VIC 8088, Australia
Full list of author information is available at the end of the article
Background

Hyperinsulinemia is a common characteristic of obesity and has been prospectively linked to the development of cardiovascular morbidity and mortality [1, 2]. The elevation in peripheral insulin concentration under both fasting and stimulated conditions has been attributed to the combined effects of increased pancreatic insulin secretion and reduced insulin clearance, physiological processes that are a function of the prevailing level of insulin resistance [3–5]. Indeed, longitudinal studies using a fed cat model [6] and intentional weight gain in healthy humans [7] indicate that reduced insulin clearance is an early adaptive phenomenon that may operate to preserve pancreatic \( \beta \)-cell function from excessive demand in the insulin resistant state. Within obese populations, upper body fat distribution, increased liver fat content, hypertension, hyperglycemia and dyslipidemia (known collectively as the metabolic syndrome), have been shown to confer lower insulin clearance [5, 8–12]. Despite its importance in the metabolism of insulin and its potential role in the aetiology of cardiovascular disease and diabetes [13], relatively little is known concerning the mechanisms responsible for impaired insulin clearance in obesity and for the recognized benefits of weight loss in this regard [14, 15].

The liver and the kidneys are the principle sites of insulin clearance from the circulation, accounting for approximately 60 and 25 % respectively of total clearance at physiological insulin levels [16], although other insulin sensitive tissues such as muscle and adipose tissue also participate to a lesser extent. Insulin uptake and degradation involves several steps, including binding to the insulin membrane receptor, cellular internalization and enzymatic degradation [17]. Our group has recently demonstrated inverse associations between resting sympathetic nervous system (SNS) activity, quantified as arterial norepinephrine concentration and whole-body norepinephrine spillover rate, peripheral arterial stiffness and insulin clearance in obese individuals with metabolic syndrome [18]. This concurs with an earlier study which showed that acute infusion of the \( \alpha_1 \)-adrenergic agonist phenylephrine during hyperinsulinemic euglycemic clamp, decreased insulin clearance by 20 % in healthy volunteers [19]. Putative mechanisms by which catecholamine stimulation may adversely impact on insulin clearance include hemodynamic alterations such as enhanced vasoconstrictor tone and microvascular rarefaction that promote insulin resistance [20, 21], reduction in hepatic or renal blood flow [22, 23] and modulation of insulin receptor numbers and/or insulin binding affinity [24, 25]. Whilst the reciprocal interplay between insulin resistance, hyperinsulinemia and SNS activation has been long appreciated [21, 26], there is a paucity of knowledge regarding their interrelationship to insulin clearance, particularly in the context of weight loss which is known to elicit both sympathoinhibition and enhanced insulin sensitivity.

The aims of the present study were (1) to examine the effects of weight loss induced by hypocaloric diet (HCD) on insulin clearance, SNS activity and vascular function and (2) to delineate the pathophysiological drivers of improvement in insulin clearance following lifestyle intervention. We hypothesized that reduction in SNS activity would predict improvement in insulin clearance.

Methods

Subjects

Seventeen overweight and obese subjects were recruited through newspaper advertisements to participate in a weight loss trial (NCT01771042). They were compared with age- and BMI-matched controls (n = 17) who had been studied previously in our laboratory (NCT00408850). Entry criteria and study methodology were identical in the two studies. Subjects were non-smokers, aged 45–65 years, with a stable body weight (±1 kg) in the previous 6 months and were not taking medications that could affect study parameters (e.g. oral hypoglycemics, cholesterol-lowering, anti-hypertensive, anti-depressant and hormone replacement therapies). Females were post-menopausal. Exclusion criteria comprised history of cardiovascular, cerebrovascular, renal, liver, or thyroid diseases and use of continuous positive airway pressure treatment. Screening tests included physical examination, electrocardiogram, biochemical tests, medical and dietary history, and measurement of supine resting blood pressure as the average of five readings after 5 min rest using a Dinamap monitor (Model 1846SX, Critikon Inc, Tampa, FL, USA). Clinical investigations were performed at baseline and after 16-weeks HCD or no treatment (controls). The project was approved by the Alfred Hospital Human Research Ethics Committee and written informed consent was obtained from each participant.

Dietary intervention

Habitual dietary intake was assessed by 4-day prospective diet records using Australian food composition tables (Foodworks 7 Professional, Xyris Software, Kenmore Hills Qld 4069). Subjects were prescribed HCD at 25 % energy deficit using a modified Dietary Approach to Stop Hypertension (DASH) eating plan [27], with higher protein and lower carbohydrate content (25 % protein, 30 % fat and 45 % carbohydrate) to maximize fat loss [28]. The DASH eating pattern has an emphasis on fruits and vegetables, low-fat dairy, wholegrain cereals, legumes and nuts, lean meats, poultry and fish.
Randomized controlled trials have established that this dietary pattern lowers blood pressure and lipid levels and favourably influences metabolic syndrome components when used as the background diet during weight reduction [27, 29, 30]. Subjects were provided with written dietary instructions, 14-day menu plans and recipes, and prepared food in their home environment. They attended fortnightly for body weight measurement and dietary counselling with the study dietician. With regards to exercise they were instructed to walk briskly for 30 min, at least 5 days per week, in accordance with the American Diabetes Association Position Statement [31] and this was monitored by 7-day pedometer. Control subjects were told to maintain their usual eating and exercise habits. Dietary intake was monitored by prospective 4-days diet records and 24-h urinalysis (collected on the day prior to SNS tests) to quantify sodium, potassium, urea and creatinine excretion. Clinical testing was performed on two separate mornings a week apart. Subjects attended at 8 am after an overnight fast and having abstained from alcohol and heavy exercise for 36 h and caffeine for 18 h. All experiments were performed in the supine position in a temperature controlled (22 °C) research room.

Glucose metabolism and insulin clearance

Participants underwent a standard 75-g oral glucose tolerance test (OGTT, Glucaid, Fronine PTY, LTD, Taren Point, NSW 2229, Australia) with 30-min blood sampling. The Matsuda insulin sensitivity index (ISI) was calculated as a measure of insulin sensitivity to endogenously produced insulin [32]. On a separate day, the euglycemic hyperinsulinemic clamp was initiated by an intravenous bolus injection of insulin (9 mU/kg; Actrapid 100 IU/ml Novo Nordisk, Gentofte, Denmark), followed by a constant infusion rate of 40 μU/kg/min. Arterialized blood glucose was clamped at 5.0 mmol/L by the clamp (mU/L), B represents basal or fasting plasma insulin (mU/L) and SS and BCP are steady-state and basal C-peptide concentrations (pmol/L) respectively. Hepatic insulin extraction (endogenous insulin clearance) was calculated as the ratio of fasting C-peptide to fasting insulin concentration (both values expressed as pmol/L). This is based on the assumption that C-peptide is secreted equimolarly with insulin but is not subjected to hepatic first-pass metabolism.

Body weight was measured in light indoor clothes without shoes using a digital scale. Body composition was determined by whole-body dual-energy X-ray absorptiometry (DEXA, GE-LUNAR Prodigy Advance PA+130510, GE Medical Systems, Lunar, Madison, WI, USA).

Norepinephrine kinetics

Fasting norepinephrine kinetics were determined on the same morning and prior to the OGTT. After cannulation of an antecubital vein and the brachial artery, fasting venous blood samples were obtained for biochemical measurements. Radioisotope dilution methodology was then used to quantify the rate at which norepinephrine released from sympathetic nerve endings enters the central plasma compartment (whole-body norepinephrine ‘spillover’ rate) [34]. This technique involves the intravenous infusion of [3H]-norepinephrine and measurement of norepinephrine specific activity and endogenous norepinephrine in arterial blood, sampled from the brachial artery, under steady-state conditions. After a priming bolus of 1.81 μCi of 1-[ring-2,5,6-3H]-norepinephrine (Perkin-Elmer, Waltham, MA, USA; specific activity, 10–30μCi/mmol), an infusion was commenced at 0.18 μCi min⁻¹, with arterial blood sampling 30 min after infusion commencement. The following calculations were performed:

Norepinephrine clearance (L/min) = \left[ \frac{\text{[3H]} - \text{norepinephrine infusion rate (dpm/min)}}{\text{[3H]} - \text{norepinephrine plasma concentration (dpm/ml)}} \right] \times 1000

Norepinephrine spillover (ng/min) = \frac{\text{plasma norepinephrine (pg/ml)} \times \text{clearance (ml/min)}}{1000}

After completion of arterial blood sampling, subjects underwent an OGTT as described above. It is of note

Insulin clearance \left( \text{ml/m}^2/\text{min} \right) \quad = \quad \frac{\text{Insulin infusion rate (mU/m}^2/\text{min)}}{\left[ \text{SS}_{i} - (B_{i} \times \text{SS}_{CP}/B_{CP}) \right]} \times 1000

where SS represents steady-state plasma insulin levels during the clamp (mU/L), B represents basal or fasting plasma insulin (mU/L) and SS and BCP are steady-state and basal C-peptide concentrations (pmol/L) respectively.
that high specific activity [3H]-norepinephrine has no physiological effects at the doses used [34].

Muscle sympathetic nerve activity
Resting multi-unit muscle sympathetic nerve activity (MSNA) activity was measured via a tungsten microelectrode inserted into a muscle nerve fascicle of the right peroneal nerve at the fibular head. Once an acceptable nerve-recording site was obtained via visual and acoustic identification of spontaneous sympathetic bursts, resting measurements were recorded over 15 min. The nerve signal was amplified (×50,000), filtered (bandpass, 700–2000 Hz) and integrated. Continuous electrocardiographic and MSNA recordings were digitised with a sampling frequency of 1000 Hz (PowerLab recording system, model ML785/BSP, AD Instruments). MSNA was manually analysed and expressed as burst frequency (bursts/min) and burst incidence (bursts/100 heartbeats), averaged over 15 min.

Cardiovascular parameters
Resting cardiac baroreflex sensitivity was estimated using the sequence method. This procedure identifies the spontaneous sequences of three or more consecutive heartbeats during which intra-arterial systolic blood pressure increased and cardiac interval lengthened (type 1 sequences) or systolic blood pressure decreased and cardiac interval shortened (type 2 sequences), with a lag of one beat. The slope of the regression line between cardiac interval and intra-arterial systolic blood pressure values was calculated for each validated sequence (when r > 0.85). Individual slopes were averaged over a 15 min recording period.

Cardiac output was quantified by transthoracic Doppler echocardiography (Vivid 7 GE Vingmed, GE Healthcare) from the left ventricular outflow tract cross-sectional diameter and the velocity time integral measurements.

Calf blood flow measurements were obtained in the left leg by venous occlusion plethysmography (D.E. Hokansen, Bellevue, WA, USA). Strain gauges were attached around the thickest part of the calf and the measured leg was supported 10 cm above heart level to empty the venous system. Twelve consecutive readings were averaged and expressed as mL per min per 100 g of tissue. Calf vascular resistance was calculated as mean arterial pressure (MAP) divided by calf blood flow. Measurements were made in the fasting state and every 30 min during OGTT to quantify the vasodilatory response to endogenous insulin.

Endothelial function was evaluated non-invasively in the index finger of the non-dominant hand by the Endo-PAT 2000 device (Itamar Medical Ltd, Caesarea, Israel). A beat-to-beat plethysmographic recording of the arterial pulse-wave was obtained over 5 min of supine rest. Brachial arterial occlusion was then induced by inflating an upper arm cuff to supra-systolic pressure (60 mmHg above systolic pressure) for 5 min, and released to elicit reactive flow-mediated hyperaemia. Pulse amplitude responses to hyperaemia were calculated from the hyperaemic fingertip as the ratio of the post deflation pulse amplitude between 90 and 120 s to the baseline pulse amplitude and adjusted for the corresponding ratio in the contralateral control hand (PAT ratio) [35].

Laboratory analyses
Plasma glucose and lipid profile were measured on a commercial analytical system (Architect C18000 analyzer, Abbott Laboratories, Illinois, USA). High sensitivity C-reactive protein (hs-CRP) was quantified by immunoturbidimetric assay, insulin and leptin by radio-immuno assay (Linco Research, Inc, Missouri, USA), C-peptide by chemiluminescent immunoassay (ADVIA Centaur, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) and non-esterified fatty acids (NEFA) by enzymatic colorimetric method (Wako Pure Chemical Industries, Ltd, Osaka, Japan). Plasma norepinephrine was assayed by high performance liquid chromatography with electrochemical detection, following extraction by alumina adsorption. [3H]-norepinephrine was assayed by liquid scintillation chromatography and corrected for loss during extraction using recoveries of internal standard. Intra-assay CVs in our laboratory are 1.3 % for norepinephrine and 2.3 % for [3H]-norepinephrine; inter-assay CVs are 3.8 and 4.5 %, respectively.

Statistical analyses
Statistical analysis was performed using SigmaStat Version 3.5 (Systat Software Inc, Point Richmond, CA, USA). Data are presented as the mean ± SEM. Baseline parameters in the two study groups were compared by un-paired t-tests and Mann–Whitney rank sum test. Two-way repeat measures ANOVA was used to test for group effects, time effects and group × time interactions, with the Holm-Sidak test for multiple post hoc comparisons. Non-parametric data were log transformed. Post-intervention changes in study parameters (Δ) were compared by un-paired t test or Mann–Whitney test as appropriate.

Sub-group analysis by baseline insulin status, was performed using a cut-point of insulin area under the curve during OGTT (AUC0–120) of 8000 mU/L per minute, to categorize subjects as hyperinsulinemic or normoinsulinemic [36]. Univariate associations between change in insulin clearance and other variables were assessed using Pearson’s correlations. Forward stepwise linear regression analysis, adjusted for age and change in body weight,
was performed to identify the independent predictors of change in insulin clearance in the HCD group. Variables with P values <0.10 in univariate analyses were entered into the regression model. Statistical significance was accepted at the P < 0.05 (two-tailed) level.

**Results**

**Subjects**

Baseline demographic, clinical and dietary characteristics of study participants are presented in Table 1. Control and HCD groups were well matched for age, anthropometrics, glucose metabolism and blood pressure. Body weight and total body fat mass decreased by −8.3 ± 0.6 % (range −3.6 to −11.6 %) and −6.2 ± 0.7 kg respectively and plasma leptin by −8.5 ± 2.1 ng/mL in the HCD group (all P < 0.001 versus control group, Table 2). Based on 4-day diet records, energy deficit averaged −543 ± 100 kcal/day, carbohydrate and saturated fat intake decreased by −6.3 ± 1.4 % and −2.9 ± 0.8 % (−12 ± 3 g/day) of energy respectively, and protein intake increased by 7.5 ± 1.2 % of energy (all P ≤ 0.001). Urinary sodium excretion decreased by −42 ± 18 mmol/day in the HCD group and −5 ± 13 mmol/day in the control group (P = 0.11), whereas potassium and urea excretion were unchanged. Pedometry records showed an increment of 1419 ± 561 steps/day in the HCD (P = 0.03).

Cholesterol profile improved significantly after weight loss: plasma LDL-cholesterol and triglyceride concentrations fell, whilst HDL-cholesterol increased compared to control subjects (all P < 0.05, Table 2). The inflammatory marker hs-CRP decreased significantly only in the HCD group.

**Glucose metabolism and insulin clearance**

Fasting glucose and insulin, and the glucose and insulin areas under the curve between time 0 and 120 min (AUC0–120) during the OGGT, decreased significantly in the HCD group (P all <0.01) and there was a commensurate reduction in HOMA-IR and an increase in Matsuda ISI (P both <0.001)(Fig. 1a, b). Clamp derived glucose utilization increased by an average of 20 ± 9 % in the HCD group (P = 0.02 versus control group) (Fig. 1c). Fasting C-peptide to insulin ratio increased from 6.3 ± 0.8 at baseline to 7.1 ± 0.9 post-weight loss in the HCD group (P = 0.09) (Fig. 1d). Exogenous insulin clearance increased from 352 ± 14 to 393 ± 21 mL/m²/min (P = 0.02) (Fig. 1e), representing and average increment of 12 ± 5 %. There were no changes in glucose or insulin parameters in the control group.

**Sympathetic nervous system activity**

Figure 2 illustrates changes in MSNA burst incidence and norepinephrine kinetics in relation to changes in body weight and insulin status in the study groups. Arterial norepinephrine concentration and calculated whole-body norepinephrine spillover rate decreased by −12 ± 5 % and −14 ± 8 % respectively in the HCD group, which did not differ significantly from changes in the control group. Satisfactory paired MSNA measurements were obtained in 10 control and 13 HCD subjects. MSNA decreased by −7 ± 3 bursts/min and −9 ± 5 bursts per 100 h in the HCD, but this did not differ significantly from changes in the control group. Sub-group analyses by baseline insulin status (hyperinsulinemic: insulin AUC0–120 10.394 ± 694 mU/L per min, n = 10; normoinsulinemic: insulin AUC0–120 5469 ± 501 mU/L per min, n = 7), showed that significant sympathoinhibition

---

**Table 1** Demographic, clinical and dietary variables of study participants

|                      | Control (n = 17) | HCD (n = 17) | P     |
|----------------------|-----------------|--------------|-------|
| Age (years)          | 56 ± 1          | 55 ± 1       | 0.87  |
| Gender (M/F)         | 10/7            | 7/10         | 0.49  |
| Number of MetS comp  | 2.7 ± 0.3       | 2.5 ± 0.3    | 0.68  |
| Clinical parameters  |                 |              |       |
| Body weight (kg)     | 97.8 ± 4.0      | 98.6 ± 4.1   | 0.89  |
| Body mass index (kg/m²) | 32.8 ± 0.9    | 33.9 ± 1.7   | 0.85  |
| Waist circumference (cm) | 106.1 ± 2.3   | 107.8 ± 2.8  | 0.63  |
| Waist to hip ratio   | 0.91 ± 0.02     | 0.91 ± 0.02  | 0.96  |
| Fasting glucose (mmol/L) | 5.8 ± 0.1     | 6.1 ± 0.2    | 0.24  |
| 2-h glucose (mmol/L) | 9.6 ± 0.1       | 10.4 ± 0.7   | 0.44  |
| Fasting insulin (mU/L) | 17.7 ± 1.6      | 18.0 ± 1.4   | 0.88  |
| HOMA-IR              | 48 ± 0.4        | 4.9 ± 0.5    | 0.90  |
| M (mg kg FFM min⁻¹)  | 9.49 ± 0.82     | 10.24 ± 0.93 | 0.55  |
| Insulin clearance (mL m² min⁻¹) | 382 ± 20   | 352 ± 14     | 0.23  |
| Triglycerides (mM/L) | 1.5 ± 0.1       | 1.7 ± 0.2    | 0.77  |
| HDL-cholesterol (mM/L) | 1.29 ± 0.07  | 1.20 ± 0.06  | 0.44  |
| LDL-cholesterol (mM/L) | 3.4 ± 0.1     | 3.9 ± 0.2    | 0.07  |
| Clinic systolic BP (mmHg) | 127 ± 4       | 121 ± 2    | 0.22  |
| Clinic diastolic BP (mmHg) | 72 ± 2       | 69 ± 2    | 0.27  |
| Clinic heart rate (bpm) | 62 ± 2        | 62 ± 2    | 0.92  |
| 7-day pedometry (steps per day) | 8021 ± 724 | 8824 ± 1100 | 0.68  |

**Habitual dietary intake**

|                      | Control (n = 17) | HCD (n = 17) | P     |
|----------------------|-----------------|--------------|-------|
| Energy (kcal/day)    | 2081 ± 158      | 2067 ± 86    | 0.69  |
| Fat (% energy)       | 34 ± 2          | 36 ± 1       | 0.32  |
| Saturated fat (% energy) | 14 ± 1        | 15 ± 1       | 0.46  |
| Protein (% energy)   | 19 ± 1          | 18 ± 1       | 0.83  |
| Carbohydrate (% energy) | 44 ± 2        | 41 ± 2       | 0.28  |
| Alcohol (% energy)   | 2 ± 2           | 2 ± 1        | 0.74  |
| 24-h urinary sodium (mmol/day) | 155 ± 20   | 157 ± 14     | 0.58  |

BP blood pressure, HOMA-IR homeostasis model assessment of insulin resistance, M steady state glucose utilization during euglycemic hyperinsulinemic clamp (mg per kg fat free mass per minute), MetS metabolic syndrome components defined as per harmonized definition.
### Table 2 Anthropometric, metabolic and cardiovascular parameters at baseline and post interventions

| Variables                      | Control Baseline | HCD Baseline | HCD Week 16 | Group × time interaction (P) |
|--------------------------------|------------------|--------------|-------------|-----------------------------|
| **Anthropometric**             |                  |              |             |                             |
| Body weight (kg)               | 97.8 ± 4.0       | 98.2 ± 4.2   | 98.6 ± 4.1  | 90.4 ± 4.0**                | <0.001 |
| Δ                              | 0.4 ± 0.4        |              |             | −8.1 ± 0.6†                 |        |
| Body mass index (kg/m²)        | 32.8 ± 0.9       | 32.9 ± 1.0   | 33.9 ± 1.7  | 31.2 ± 1.7***               | <0.001 |
| Δ                              | 0.2 ± 0.2        |              |             | −2.7 ± 0.2†                 |        |
| Waist circumference (cm)       | 106.1 ± 2.3      | 106.5 ± 2.2  | 107.8 ± 2.8 | 100.3 ± 2.8***              | <0.001 |
| Δ                              | 0.4 ± 0.4        |              |             | −7.5 ± 0.9†                 |        |
| Waist to hip ratio             | 0.91 ± 0.02      | 0.92 ± 0.02  | 0.91 ± 0.02 | 0.89 ± 0.01***              | 0.001  |
| Δ                              | 0.0 ± 0.0        |              |             | −0.03 ± 0.01†               |        |
| Total body fat mass (kg)       | 38.0 ± 2.9       | 38.0 ± 3.0   | 42.0 ± 2.7  | 35.8 ± 3.1***               | <0.001 |
| Δ                              | 0.1 ± 0.3        |              |             | −6.2 ± 0.7†                 |        |
| **Metabolic and biochemical**  |                  |              |             |                             |
| Fasting glucose (mmol/L)       | 5.8 ± 0.1        | 5.9 ± 0.1    | 6.1 ± 0.2   | 5.8 ± 0.1**                 | 0.03   |
| Δ                              | 0.0 ± 0.1        |              |             | −0.3 ± 0.1†                 |        |
| Fasting insulin (mU/L)         | 18.8 ± 1.7       | 20.4 ± 1.6*  | 18.0 ± 1.4  | 13.8 ± 1.2***               | <0.001 |
| Δ                              | 1.7 ± 0.9        |              |             | −4.2 ± 0.7†                 |        |
| Triglycerides (mmol/L)         | 1.5 ± 0.1        | 1.4 ± 0.1    | 1.7 ± 0.2   | 1.1 ± 0.1***                | 0.02   |
| Δ                              | −0.1 ± 0.1       |              |             | −0.6 ± 0.2†                 |        |
| HDL-cholesterol (mmol/L)       | 1.29 ± 0.07      | 1.20 ± 0.06* | 1.21 ± 0.05 | 1.25 ± 0.07                 | 0.02   |
| Δ                              | −0.09 ± 0.04     |              |             | 0.04 ± 0.03†                |        |
| LDL-cholesterol (mmol/L)       | 3.4 ± 0.1        | 3.4 ± 0.2    | 3.8 ± 0.2   | 3.5 ± 0.2**                 | 0.02   |
| Δ                              | 0.0 ± 0.1        |              |             | −0.3 ± 0.1†                 |        |
| NEFA (mEq/L)                   | 0.53 ± 0.04      | 0.51 ± 0.04  | 0.57 ± 0.05 | 0.55 ± 0.04                 | 0.93   |
| Δ                              | −0.02 ± 0.03     |              |             | −0.02 ± 0.04                |        |
| Leptin (ng/mL)                 | 18.7 ± 4.6       | 19.1 ± 3.6   | 21.6 ± 4.7  | 13.1 ± 3.4***               | <0.001 |
| Δ                              | 0.4 ± 1.6        |              |             | −8.5 ± 2.1†                 |        |
| High sensitivity CRP (mg/L)    | 3.3 ± 0.8        | 3.5 ± 0.9    | 3.2 ± 0.6   | 2.2 ± 0.4*                  | 0.12   |
| Δ                              | 0.2 ± 0.6        |              |             | −0.9 ± 0.3†                 |        |
| Creatinine clearance (mL/min)  | 150 ± 11         | 147 ± 9     | 140 ± 10    | 118 ± 7***                  | 0.06   |
| Δ                              | −3 ± 6           |              |             | −22 ± 10                    |        |
| **Cardiovascular**             |                  |              |             |                             |
| Clinic MAP (mmHg)              | 92 ± 3           | 95 ± 3       | 89 ± 2      | 86 ± 2*                     | 0.007  |
| Δ                              | 3 ± 2            |              |             | −3 ± 1†                     |        |
| Clinic heart rate (bpm)        | 62 ± 2           | 61 ± 2       | 62 ± 2      | 59 ± 2*                     | 0.41   |
| Δ                              | −2 ± 1           |              |             | −3 ± 1                      |        |
| Cardiac BRS (ms/mmHg)          | 15.7 ± 2.2       | 15.7 ± 1.9   | 18.0 ± 2.6  | 23.7 ± 2.9***               | 0.16   |
| Δ                              | 0.0 ± 2.2        |              |             | 5.8 ± 2.3                   |        |
| Calf vascular resistance (units)| 53.0 ± 6.7       | 57.4 ± 4.4   | 51.3 ± 4.9  | 47.1 ± 3.3                  | 0.18   |
| Δ                              | 4.4 ± 4.6        |              |             | −4.2 ± 3.9                  |        |
| Finger reactive hyperaemic index| 2.35 ± 0.15      | 2.42 ± 0.16  | 2.38 ± 0.19 | 2.26 ± 0.15                 | 0.44   |
| Δ                              | 0.07 ± 0.13      |              |             | −0.12 ± 0.20                |        |
| PAT ratio                      | 0.68 ± 0.09      | 0.67 ± 0.09  | 0.67 ± 0.10 | 0.62 ± 0.09                 | 0.77   |
| Δ                              | −0.01 ± 0.10     |              |             | −0.05 ± 0.11                |        |
| Cardiac output (L/min)         | 5.3 ± 0.3        | 5.6 ± 0.4    | 5.5 ± 0.4   | 5.4 ± 0.4                   | 0.30   |
| Δ                              | 0.3 ± 0.2        |              |             | −0.1 ± 0.2                  |        |

*BRS baroreflex sensitivity, CRP C-reactive protein, MAP mean arterial pressure, NEFA non-esterified fatty acids, PAT peripheral arterial tonometry

* P < 0.05, ** P < 0.01 and *** P < 0.001 versus Baseline; † P < 0.05 and ‡ P < 0.01 versus Control Group
Fig. 1 Changes in insulin sensitivity and insulin clearance in control and hypocaloric diet (HCD) groups (week 16 minus baseline measurements).

a Homeostasis model assessment of insulin resistance (HOMA-IR): group × time interaction, P < 0.001.

b Matsuda insulin sensitivity index (ISI): group × time interaction, P < 0.001.

c Steady state glucose utilization during euglycemic clamp (M): group × time interaction, P = 0.02.

d Fasting C-peptide to insulin ratio: group × time interaction, P = 0.06.

e Insulin clearance: group × time interaction, P = 0.03. *P < 0.05 and ***P < 0.001 versus control group.
(reduction in whole-body norepinephrine spillover rate) was only attained in hyperinsulinemic subjects following HCD, despite similar weight loss in the two sub-groups (Fig. 2f).

Cardiovascular parameters
Cardiovascular parameters are presented in Table 2. Clinic MAP was reduced and spontaneous cardiac baroreflex sensitivity was enhanced following weight loss.
Cardiac output, finger reactive hyperaemic response and PAT ratio were not significantly altered with weight loss. Fasting calf vascular resistance decreased non-significantly after weight loss ($P = 0.17$ versus control) and there was a greater vasodilatory response to endogenous insulin during the OGTT in HCD, but not the control group (Fig. 3). Baseline insulin status did not modify changes in cardiovascular parameters following HCD.

**Correlation and regression analyses**

Post weight loss change in exogenous insulin clearance ($n = 17$) correlated positively with changes in HDL-cholesterol ($r = 0.53$, $P = 0.03$), cardiac output ($r = 0.44$, $P = 0.08$), $M$ ($r = 0.45$, $P = 0.07$) and inversely with changes in fasting calf vascular resistance ($r = -0.63$, $P = 0.007$), calf vascular resistance during OGTT ($AUC_{0-120}$) ($r = -0.58$, $P = 0.01$) and $hs$-CRP ($r = -0.49$, $P = 0.05$) (Fig. 4). Post weight loss change in fasting C-peptide to insulin ratio correlated positively with changes in Matsuda ISI ($r = 0.52$, $P = 0.03$) and finger reactive hyperaemic response ($r = 0.49$, $P = 0.04$) and inversely with changes in glucose $AUC_{0-120}$ ($r = -0.61$, $P = 0.009$) and HOMA-IR ($r = -0.53$, $P = 0.03$) (Fig. 4). Changes in anthropometrics, sympathetic neural parameters (arterial norepinephrine concentration, norepinephrine spillover rate and MSNA), creatinine clearance, and urinary sodium and potassium excretion did not correlate with change in exogenous insulin clearance or hepatic insulin extraction.

Stepwise regression analyses are summarized in Table 3. Improvement in exogenous insulin clearance after weight loss intervention was independently predicted by reduction in fasting calf vascular resistance and increase in HDL-cholesterol, which together explained 55% of the variance. Improvement in hepatic insulin extraction after weight loss was independently predicted by enhanced glucose tolerance (reduced glucose $AUC_{0-120}$) and finger reactive hyperaemic response, which together explained 64% of the variance. In turn, change in fasting calf vascular resistance was independently predicted by improvement in insulin clearance and reduction in $hs$-CRP; enhancement in vasodilatory response during OGTT was predicted by improvement in insulin sensitivity; whilst change in the reactive hyperaemic response was inversely and independently predicted by change in MAP. Regarding SNS parameters, change in arterial norepinephrine concentration post weight loss was the strongest independent predictor of change in MAP, whilst reduction in MSNA was a function of improved baroreflex sensitivity (Table 3).

**Discussion**

Hyperinsulinemia is considered to be a core component in the pathophysiology of obesity-related comorbidities [1, 2]. The focus of this study was insulin clearance, a key determinant of fasting and postprandial plasma insulin levels, which is known to be reduced in obesity particularly when features of the metabolic syndrome are present [5]. We simultaneously evaluated changes in sympathetic neural parameters, vascular and metabolic function, and anthropometrics following a HCD in order to ascertain the drivers of improvement in insulin clearance during lifestyle intervention. There are three main
findings from our study. First, that weight loss of −8.3% of baseline body weight elicited significant improvement in whole-body insulin clearance (by 12%) and a non-significant increase in fasting hepatic insulin extraction (by 17%) within our cohort. Second, that although vascular responses to weight loss were heterogeneous,

**Fig. 4** Univariate correlates of change in whole-body insulin clearance and hepatic insulin extraction (fasting C-peptide to insulin ratio) in the HCD group (n = 17). a Change in fasting calf vascular resistance (r = −0.63, 0.007). b Change in steady state glucose utilization during euglycemic hyperinsulinemic clamp (M) (r = 0.45, P = 0.07). c Change in plasma HDL-cholesterol concentration (r = 0.53, P = 0.03). d Change in finger reactive hyperaemic index (r = 0.49, P = 0.04). e Change in Matsuda insulin sensitivity index (ISI) (r = 0.52, P = 0.003). f Change in glucose area under the curve (AUC0–120) during oral glucose tolerance test (r = −0.61, P = 0.009)
reduction in calf vascular resistance was the strongest independent predictor of improvement in exogenous insulin clearance, whilst improvements in endothelial function (quantified as the finger reactive hyperaemic response) and glucose tolerance predicted improvement in endogenous insulin clearance. Third, that the sympathoinhibition attained following HCD was modulated by baseline insulin status and did not correlate directly with changes in insulin clearance.

Relatively few studies to date have examined the effects of caloric restriction on insulin clearance in obese adults and these have pertained to changes in endogenous, but not exogenous insulin clearance [3, 15, 37, 38]. Bosello et al. reported an average increase of 63 % in fasting C-peptide to insulin ratio after 3-weeks of a very low caloric diet (VLCD, 320 kcal/day) which resulted in a 6.3 % body weight loss [37]. Polonsky et al. studied changes in 24-h endogenous insulin clearance in different metabolic sub-groups following a VLCD (600 kcal/day) over a 6-week period [38]. Weight loss of 16–19 % in body weight translated to improvements of 30–50 % in insulin clearance, with greatest benefits in type 2 diabetic subjects. In another study 9.8 % weight loss over 9 weeks increased endogenous insulin clearance in response to graded glucose infusion by 42 % [3]. In our study, improvement in endogenous insulin clearance averaged 17 % which is smaller in magnitude than the aforementioned studies. It is likely that these differences may be explained by the more moderate caloric restriction and longer intervention period utilized in our study. Both the level of negative energy balance and weight loss per se are known to influence changes in insulin sensitivity, metabolic and autonomic parameters [39, 40].

The salient finding of our study is that improvement in vascular parameters (reduction in calf vascular resistance and increase in finger reactive hyperaemic index), independent of weight changes, delineated those subjects who gained a benefit in insulin clearance following HCD from those who did not. Moreover, this relationship was bidirectional as enhanced insulin clearance post weight loss independently predicted reduction in calf vascular resistance. These data concur with previously published studies showing that hypertension is associated with decreased insulin clearance [10, 12] and that administration of the α1-adrenergic agonist phenylephrine during hyperinsulinemic euglycemic clamp acutely diminishes insulin clearance in healthy volunteers [19]. Changes in peripheral vascular tone may impact on insulin clearance directly or indirectly via effects on insulin sensitivity. Impaired transcapillary transport of insulin caused by either decreased blood flow or permeability, or decreased capacity to vasodilate, could hinder the efflux of insulin from the intravascular space, hence decreasing insulin clearance [10, 20, 41], as well as impacting on insulin action [41, 42]. Our findings support the notion that insulin clearance and sensitivity are closely aligned [5–7] as improvement in Matsuda ISI and clamp derived glucose utilization post weight loss were positively associated with both measures of insulin clearance, and suggest that vascular function may be a common pathophysiological mediator of this association.

Our data underscore the potential importance of endothelial function in relation to insulin clearance at both the microvascular level and in skeletal muscle vasculature. Post ischemic finger reactive hyperaemia is a complex response, reflecting changes in digital blood
flow and digital microvessel dilation, processes that depend on nitric oxide synthesis [35, 43]. Similarly, the vasodilatory response to endogenous insulin in skeletal muscle vasculature during OGTT is mediated by insulin-stimulated production of nitric oxide [44]. In our study, post weight loss improvement in these vascular parameters related to enhanced insulin clearance and insulin sensitivity and reduction in MAP and inflammatory milieu (plasma hs-CRP concentration). Other factors that may have contributed to improvement in endothelial parameters include weight loss and/or DASH diet induced changes in lipid profile (reduced plasma triglyceride and LDL-cholesterol and increased HDL-cholesterol concentrations) and reduction in glycemia [29, 45, 46]. Enhanced plasma nitrite level in response to reactive hyperaemia, has been reported in obese hypertensive subjects after 2-week consumption of a DASH eating plan, and suggest an upregulation of nitric oxide bioavailability [47]. Our finding of enhanced vasodilatory response to OGTT following HCD is relevant to postprandial glucose disposal and cardiovascular risk and concurs with other published data [48]. It is notable that the Insulin Resistance Atherosclerosis Study, which followed 748 non-diabetic participants over 5-years to examine prospective changes in insulin clearance, observed that higher systolic blood pressure, plasma triglycerides and waist circumference at baseline were associated with future decline of insulin clearance, whereas higher HDL-cholesterol level predicted an increase in insulin clearance [12]. These findings likely reflect the convergence of metabolic syndrome components and insulin resistance on endothelial function and support our findings regarding the benefits of weight loss. It merits emphasis, that vascular responses to weight loss were variable within our cohort. One explanation for this is that baseline differences in insulin status influenced the degree of sympathoinhibition attained independent of weight change. Insulin status has also been shown to affect the benefits of weight loss on flow-mediated vasodilation with favourable changes being manifest only in hyperinsulinemic individuals [36].

SNS activation promotes vasoconstriction, vascular structural changes, impaired endothelial function and capillary rarefaction and has been linked to the development of insulin resistance in both prospective population [49] and human experimental studies [21]. The level of sympathoinhibition attained in the present study was smaller than what we have previously reported in other cohorts with similar weight loss [50], and correlated with improvements in MAP, but not insulin clearance. Our subgroup analysis highlights that change in plasma insulin levels is a key determinant of the sympathoinhibitory response following weight loss [26].

The strengths of our study are the detailed characterization of study participants and the use of gold standard methodology to evaluate insulin sensitivity and clearance and SNS activity. The limitations of our study include the relatively small sample size and non-randomized study design. Also our study does not differentiate between the effects of negative energy balance and weight loss per se. Finally, the role of other unmeasured factors, for instance adiponectin, which may have impacted on endothelial function and insulin clearance, merits further investigation [51].

Conclusions

Our study demonstrates a bidirectional inter-relationship between changes in insulin clearance and vascular endothelial function during the course of a weight loss program. Improvement in risk factors associated with the metabolic syndrome, namely insulin resistance, hyperglycemia, proinflammatory state, blood pressure and HDL-cholesterol may underlie the vascular benefit and enhancement in insulin clearance.

Abbreviations

AUC0–120: area under the curve during oral glucose tolerance test (0–120 min); BMI: body mass index; DASH: dietary approaches to stop hypertension; HCD: hypocaloric diet; hs-CRP: high sensitivity C-reactive protein; HOMA-IR: homeostasis model assessment of insulin resistance; M: steady state glucose utilization during euglycemic clamp; M/I: steady state glucose utilization during euglycemic clamp, adjusted for steady-state plasma insulin concentration; MAP: mean arterial pressure; Matsuda ISI: Matsuda insulin sensitivity index; MSNA: muscle sympathetic nervous activity; OGTT: oral glucose tolerance test; PAT: peripheral arterial tonometry; SNS: sympathetic nervous system; VLCD: very low calorie diet.

Authors’ contributions

NES, EAL, JBD and GWL conceived the study and contributed to the interpretation of the data. SP and NE performed laboratory analyses. NES, MTG, CIS, EAL, DK, DH, PjN, JAM, SK and MPS collected clinical data. NES performed statistical analysis and wrote the manuscript. All authors read and approved the final manuscript.

Author details

1 Laboratory of Human Neurotransmitters, Baker DI Heart and Diabetes Institute, P.O. Box 6492, St Kilda Road Central, Melbourne, VIC 8008, Australia. 2 Laboratory of Neurovascular Hypertension and Kidney Disease, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. 3 Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. 4 Laboratory of Cardiovascular Nutrition, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. 5 Alfred Baker Medical Unit, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. 6 Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. 7 Department of Physiology, Monash University, Melbourne, VIC, Australia. 8 Department of Primary Health Care, Monash University, Melbourne, VIC, Australia. 9 Department of Physiology, University of Melbourne, Melbourne, VIC, Australia.

Acknowledgements

We wish to thank the study participants for their time, cooperation and effort, and research nurses Donna Vizi (Alfred Baker Medical Unit) and Louise Hammond (Human Neurotransmitters Laboratory) for their excellent assistance. This study was funded by a Diabetes Australia Millennium Grant in type 2 diabetes to NES. JBD, MPS and GWL are supported by NHMRC Fellowships. We also wish to acknowledge the Victorian Government’s Operational Infrastructure Support Program.
Compliance with ethical guidelines

Competing interests

NES, MG, CIS, EAL, SAE, NE, DK, DH and SK have nothing to declare. JBD is a consultant for Apollo Endosurgical, Bariatric Advantage, and is a member of the Optifast® Medical Advisory Board for Nestle Health, Australia and the Saxenda Advisory Board for Novo Nordisk. JAM has received research grants and teaching honoraria from Medtronic. PJN has consultative and advisory board associations with Merck Sharp & Dohme and Astra Zeneca. MPS serves on scientific advisory boards for Abbott Pharmaceuticals, Novartis Pharmaceuticals and Medtronic and has received research support and travel support, lecture fees and honoraria from Abbott, Novartis, Server, Boehringer Ingelheim and Medtronic. GWA has acted as a consultant for Medtronic, Pfizer and Wyeth Pharmaceuticals for presentations. These organizations played no role in the design, analysis or interpretation of data described here, nor in the preparation, review, or approval of the manuscript.

Received: 9 July 2015 Accepted: 9 August 2015

Published online: 22 August 2015

References

1. Xu P, Wu Y, He G, He K (2013) Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies. Am J Clin Nutr 98:1543–1554
2. The DECODE Insulin Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256
3. Jones CNO, Abbasi F, Carantoni M, Polonsky KS, Reaven GM (2000) Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab 278:E501–E508
4. Erdman J, Mayr M, Oppel U, Sypherdon O, Wagenpfeil S, Schusdziarra V (2009) Weight-dependent differential contribution of biological insulin secretion and clearance to hyperinsulinaemia of obesity. Regul Pept 152:1–7
5. Marin IM, Frontoni S, Succurro E, Artuti F, Fiorentino TV, Sciaccia A, Perticone F, Sesti G (2014) Differences in insulin clearance between metabolically healthy and unhealthy obese subjects. Acta Diabetol 51:257–261
6. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, Bergman RN (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 49:2116–2125
7. Erdmann J, Kallabas B, Oppel U, Sypherdon O, Wagenpfeil S, Schusdziarra V (2008) Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol Endocrinol Metab 294:E568–E575
8. Peiris A, Mueller RA, Smith GA, Struve MF, Kissebah AH (1986) Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78:1648–1657
9. Kotronen A, Veikkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293:E1709–E1715
10. Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin P (1997) Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension 29:111–114
11. Marin IM, Frontoni S, Succurro E, Artuti F, Fiorentino TV, Sciaccia A, Hribal ML, Perticone F, Sesti G (2013) Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 8:e77440
12. Lee CC, Lorenzo C, Haffner SM, Wagenknecht LE, Goodarzi MO, Stefanovskii D, Norris JM, Rejesus RJ, Hanley AJ (2013) Components of metabolic syndrome and 5-year change in insulin clearance—the Insulin Resistance Atherosclerosis Study. Diabetes Obes Metab 15:441–447
13. Lee CC, Haffner SM, Wagenknecht LE, Lorenzo C, Norris JM, Berlan RN, Stefanovskii D, Anderson AM,Rotter JJ, Goodarzi MO, Hanley AJ (2013) Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans. Diabetes Care 36:901–907
14. Bojesen-Moller KN, Dirksen C, Jorgensen NB, Jacobsen SH, Hansen DL, Worm D, Naver L, Kristiansen VB, Holst JJ, Madsbad S (2013) Increased hepatic insulin clearance after Roux-en-Y gastric bypass. J Clin Endocrinol Metab 98:E1066–E1071
15. Svendsen PF, Jensen FK, Holst JJ, Haugaard SB, Nils L, Madsbad S (2012) The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scand J Clin Lab Invest 72:410–419
16. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA (1983) Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 244:E517–E527
17. Mora MEV, Scarfone A, Calvani M, Greco AV, Mingrone G (2003) Insulin clearance in obesity. J Am Coll Nutr 22:487–493
18. Straznicky NE, Grima MT, Lambert EA, Sari CI, Eikelis N, Nestel PJ, Phillips S, Hering D, Karapanagiotidis S, Dixon JB, Schlach MP, Lambert GW (2015) Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome. J Clin Endocrinol Metab 100:1544–1550
19. O’Callaghan CJ, Komersova K, Louis WJ (1998) Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. Hypertension 31:104–109
20. Egan BM (1991) Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes 15:133–139
21. Jamerson KA, Julius S, Gubrandsdottir T, Anderson O, Brant DO (1993) Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21:618–623
22. Richardson PD, Withington PG (1981) Liver blood flow. II. Effects of drugs and hormones on liver blood flow. Gastroenterology 81:356–375
23. Schnetterer L, Muller M, Faehling P, Diepolder C, Gallenkamp A, Zanaschka G, Findl O, Strenk K, Mensik C, Tscherno E, Eichler HG, Woltz M (1997) Renal and ocular hemodynamic effects of insulin. Diabetes 46:1868–1874
24. Joost HG, Quentin SH (1984) Effects of chemical sympathectomy on insulin receptors and insulin action in isolated rat adipocytes. J Pharmacol Ther 229:839–844
25. Klein HH, Matthaei S, Drenkhan M, Ries W, Scriba PC (1991) The relationship between insulin binding, insulin activation of insulin-receptor tyrosine kinase, and insulin stimulation of glucose uptake in isolated rat adipocytes. Effects of isoprenaline. Biochem J 274:787–792
26. Rowe JH, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L (1981) Effect of insulin and glucose infusions on sympathoetic nervous system activity in normal man. Diabetes 30:219–225
27. Appel LJ, Moore T, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Kanaran C (1997) A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336:1117–1124
28. Layman DK, Boleua RA, Erickson DJ, Painter JE, Shue H, Sather C, Christou P (2003) A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women. J Nutr 133:411–417
29. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER, Lin PH, Kanaran C, Most-Windhouser NM, Moore TJ, Swain JF, Bales CW, Proshcan MA (2001) Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 74:80–89
30. Azadbakht L, Mirrman P, Esmailzadeh A, Azizi T, Azizi F (2005) Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 28:2823–2831
31. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tabas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
32. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470
33. Castillo MJ, Scheen AJ, Letinheye MR, Lebefvre P (1994) How to measure insulin clearance. Diabetes Metab Rev 10:119–150
34. Esler M, Jackman G, Bobik A, Kelleher D, Jennings G, Leonard P, Skews H, Korner P (1979) Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 25:1461–1470
35. Hamburg NM, Keyses MJ, Larson MG, Vasen RS, Schnabel R, Prude MM, Mitchell GF, Scheffy J, Vita JA, Benjamin EJ (2008) Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framing- 
ham Heart Study. Circulation 117:2467–2474
36. Bigornia SJ, Farb MG, Tiwari S, Karki S, Hamburg NM, Vita JA, Hess DT, LaValley MP, Apovian CM, Gocke N (2013) Insulin status and vascular responses to weight loss in obesity. J Am Coll Cardiol 62:2297–2305
37. Bosello O, Zamboni M, Arrellini F, Zocca I, Begamo-Andreis IA, Smacchia C, Milani MP, Cominacini L (1990) Modification of abdominal fat and hepatic insulin clearance during severe caloric restriction. Ann Nutr Metab 34:359–365
38. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR (1994) Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 43:871–877
39. Assali AR, Naror A, Beigel Y, Shafer Z, Hershcovici T, Fainaru M (2001) Insulin resistance in obesity: body weight or energy balance? J Endocrinol 171:293–298
40. Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Chopra R, Masuo K, Esler MD, Sari CI, Lambert GW, Lambert EA (2011) The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 96:E503–E508
41. Sjostrand M, Gudbjornsdottir S, Strindberg L, Lonroth P (2005) Delayed transcapillary delivery of insulin to muscle interstitial fluid after oral glucose load in obese subjects. Diabetes 54:152–157
42. Prior SJ, Blumenthal JB, Katzel LI, Goldberg AP, Ryan AS (2014) Increased skeletal muscle capillarization after aerobic exercise training and weight loss improves insulin sensitivity in adults with IGT. Diabetes Care 37:1469–1475
43. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitral D, Ganz P (2006) Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 101:545–548
44. Kim J, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113:1888–1904
45. Blumenthal JA, Babyak MA, Hindrlfter A, Watkins LL, Graighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A (2010) Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the encore study. Arch Intern Med 170:126–135
46. Riwanto M, Landmesser U (2013) High density lipoproteins and endothelial function: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 54:3227–3243
47. Lin PH, Allen JD, Li YJ, Yu M, Lien LF, Svetkey LP (2012) Blood pressure-lowering mechanisms of the DASH dietary pattern. J Nutr Metab Article ID 472396:1–10
48. Haspicova M, Milek D, Siklova-Vitkova M, Wedeklova Z, Hejnova J, Bajzova M, Stich V, Polak J (2011) Post-prandial endothelial dysfunction is ameliorated following weight loss in obese premenopausal women. Med Sci Monit 17:CR634–CR639
49. Flaa A, Akesnes TA, Kjeldsen SE, Eide I, Rostrup M (2008) Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism Clin Exp 57:1422–1427
50. Straznicky NE, Lambert EA, Nestel PJ, McGarne MT, Dawood T, Schlaich MP, Masuo K, Esler MD, deCourten B, Mariani JA, Esler MD, Scatratous MP, Chopra R, Sari CI, Paul E, Lambert GW (2010) Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes 59:71–79
51. Azuma M, Chihara Y, Yoshimura C, Murase K, Kamada S, Tachikawa R, Matsumoto T, Inouchi M, Tanizawa K, Handa T, Oga T, Mishima M, ChIn K (2015) Association between endothelial function (assessed on reactive hyperemia peripheral arterial tonometry) and obstructive sleep apnea, visceral fat accumulation, and serum adiponectin. Circ J 79:1381–1389

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit